Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
04/01/2025 08:30 AM EDT GlobeNewswire Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
03/24/2025 07:05 AM EDT GlobeNewswire Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
03/19/2025 08:05 AM EDT GlobeNewswire Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
03/11/2025 08:45 AM EDT PR Newswire Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
03/10/2025 08:45 AM EDT PR Newswire Moleculin to Present at the 37th Annual ROTH Conference
03/06/2025 08:30 AM EST PR Newswire Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
03/03/2025 08:30 AM EST PR Newswire Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
02/25/2025 12:35 PM EST PR Newswire Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules
02/13/2025 01:05 PM EST PR Newswire Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
02/13/2025 09:25 AM EST PR Newswire Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Page

Additional News

As of April 3, 2025 • 7:01 PM ET

Date/Time Source News Release
04/01/2025 09:55 AM EDT Zacks Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
03/31/2025 05:09 PM EDT SeekingAlpha Moleculin Biotech files to sell 18.2M shares of common stock for holders
03/26/2025 12:00 PM EDT Zacks All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
03/25/2025 04:57 AM EDT SeekingAlpha Moleculin biotech highlights pivotal Phase 3 trials for Annamycin in AML with interim results expected in 2025
03/24/2025 10:50 AM EDT SeekingAlpha Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
03/24/2025 07:31 AM EDT SeekingAlpha Moleculin Biotech GAAP EPS of -$6.32
03/21/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Friday, March 21st, 2025
03/21/2025 05:31 AM EDT US Earnings Reports Expected earnings - Moleculin Biotech Inc.
12/13/2024 05:17 PM EST SeekingAlpha Moleculin Biotech files for stock and warrants offering
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Moleculin Biotech Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.